Everpure, Inc.
Everpure is executing far better than its trailing FY2026 numbers suggest, but at $127.43 the stock already prices in a much cleaner FY27-FY28 ramp than the company has earned, despite 142.84x P/E, 8.48x P/S, negative free cash flow, and hyperscaler timing risk.
The core issue is not whether Everpure is improving. It is. The issue is whether that improvement is still underappreciated at $127.43. The answer looks no. Management just laid out a much stronger FY27 than the market had expected, with $4.3B-$4.4B of revenue and $780M-$820M of operating profit, after Q4 delivered $1.06B of revenue, $226M of operating profit, and 14.0% EBITDA margin, up 690 bps sequentially. Large-deal momentum was also real, with RPO up 40% and deals over $5M up 80%. This is not a broken story.
But the stock is no longer priced for an improving story. It is priced for a sustained, low-friction scaling story. That distinction matters. FY2026 still showed only $3.7B of revenue growth of 3.4%, EPS of $0.49, down 40.0%, operating margin of just 3.6%, net margin of -21.9%, and FCF of -$0.2B. Against that base, investors are paying 142.84x P/E, 8.48x P/S, and 23.46x book. Even if FY27 unfolds close to plan, the market is already discounting a lot of that upside after the stock's 65.22% three-month run and position 2.9% below the all-time high.
The bear case depends on three things. First, margin normalization is not linear. Management explicitly called out rapid NAND and component inflation, with pricing only partially catching up after an approximately 20% product price increase on Feb. 9. Second, hyperscaler revenue remains back-half weighted and lumpy, tied to customer buildout schedules and testing. Third, the 1touch deal is 1.5% dilutive to FY27 operating profit before turning accretive within 24 months, so reported progress may be less clean than the headline AI narrative suggests.
Conviction stays at Medium, not High, because execution has been undeniably strong. Everpure has beaten EPS in 8 straight quarters, including a +20.7% beat in the most recent report, and the balance sheet is healthy enough to absorb volatility. If the company proves it can convert AI demand into durable free cash flow and maintain operating discipline through the FY27 ramp, the sell case weakens. At this price, though, the market is giving full credit before those proof points are in hand.
Quant call (SELL) diverges from analyst consensus (Strong Buy: 14 buy / 1 hold / 1 sell) — resolve explicitly.
Price is what you pay; value is what you get.
Forward earnings power is improving fast, but the stock is already capitalizing a near-best-case path. FY27 guidance points to $4.3B-$4.4B of revenue and $780M-$820M of operating profit, which is a huge step up from FY2026's 3.6% operating margin, yet the current 142.84x trailing P/E leaves little protection if gross margin recovery or hyperscaler timing slips. The moat looks better today than a year ago because enterprise demand, Evergreen, and the first EXA customer show product relevance, but 3 to 5 years out this remains a competitive AI infrastructure market where differentiation can narrow unless Everpure sustains its Innovation Investment score of 100 with durable software and service attach. AI is a real tailwind here, not a slogan, but it also accelerates customer qualification cycles, hardware substitution risk, and hyperscaler bargaining power, while higher rates at 4.96% on the 10-year make long-duration growth stories with negative free cash flow less forgiving.
- FY27 revenue guidance of $4.3B-$4.4B implies about 18.8% growth at the midpoint, a sharp acceleration from FY2026 revenue growth of 3.4%.
- Valuation is extreme at 142.84x P/E and 8.48x P/S, versus peer averages of 23.8x and 4.7x, with the stock at $127.43, only 2.9% below the high.
- Operating improvement is real, but not fully de-risked: FY2026 operating margin was only 3.6%, free cash flow was -$0.2B, and Q1 FY27 gross margin faces pressure from input costs before pricing catches up.
- Guidance strengthened materially: management guided FY27 revenue to $4.3B-$4.4B and FY27 operating profit to $780M-$820M, implying about 26% operating profit growth at the midpoint.
- Demand indicators were strong in Q4, with RPO up 40%, deals over $5M up 80% y/y, and management stating Q4 and Q1 demand was demand-led rather than pricing-led.
- Execution has been consistent: Everpure has delivered 8 straight EPS beats, including +20.7%, +18.2%, and +19.0% beats in the last eight reports.
- The balance sheet is not the problem, with Debt/EBITDA 0.59, Debt/Equity 0.15, and a 1.44 current ratio, giving the company room to fund growth despite near-term cash flow pressure.
- Current valuation already discounts a lot of the FY27 ramp: 142.84x P/E, 23.46x P/B, and 8.48x P/S are difficult to defend against FY2026 EPS of $0.49, down 40.0% y/y.
- Cash generation remains weak relative to the market cap, with FCF of -$0.2B and a net margin of -21.9%, even after revenue grew to $3.7B.
- The recent move has compressed upside and increased setup risk: shares are up 22.56% in 1 week, 26.89% in 1 month, 65.22% in 3 months, and sit 65.8% above the 200-day average.
- Management itself flagged near-term friction, including component shortages, pricing volatility, Q1 product gross margin at the low end of 65%-70% ex-hyperscaler, and a 1.5% FY27 operating profit dilution from 1touch.
| Metric | Value | Context |
|---|---|---|
| Current price | $127.43 | Reference price for the call |
| Quant price target | $69.95 | -45.1% vs current, Low confidence, earnings_growth_blend |
| FY2026 revenue | $3.7B | +3.4% YoY |
| FY2026 EPS | $0.49 | -40.0% YoY |
| FY2026 operating margin | 3.6% | Up from 2.7% in prior FY |
| FY2026 net margin | -21.9% | Still deeply negative despite revenue growth |
| Valuation | 142.84x P/E | 8.48x P/S | 23.46x P/B | Vs peers at 23.8x P/E and 4.7x P/S |
| FY27 guidance | $4.3B-$4.4B revenue | $780M-$820M operating profit | About 18.8% revenue growth and 26% operating profit growth at midpoint |
| Balance sheet | 0.15 Debt/Equity | 0.59 Debt/EBITDA | 1.44 current ratio | Leverage is manageable |
| Free cash flow | -$0.2B | Weak cash conversion despite growth narrative |
| Price action | +22.56% 1W | +26.89% 1M | +65.22% 3M | Shares are 65.8% above the 200-day average |
| 52-week position | $56.78-$131.29 | Current price is 2.9% below the high |
The biggest risk to a SELL is that Everpure converts its AI and hyperscaler pipeline into sustained operating leverage faster than expected, especially if FY27 operating profit reaches $820M and the emerging $21B intelligence market proves monetizable sooner than the market currently assumes.
The next catalyst is the December 1, 2026 earnings report, where investors will test whether Q1 revenue of $990M-$1.01B and operating profit of $125M-$135M can hold despite input-cost pressure and shipment timing.
FY27 revenue guidance implies ~19% growth as enterprise and hyperscale momentum builds.
This broad and increasing momentum is reflected in our strong FY '27 revenue guidance of almost 19% year-over-year growth at the midpoint which Tarek will also discuss in more detail.
For Q1, we anticipate revenue to be in the range of $990 million to $1.01 billion, representing approximately a 28% increase year-over-year at the midpoint. We expect operating profit to be in the range of $125 million to $135 million, representing approximately a 57% increase year-over-year at the midpoint.
For fiscal year '27, we anticipate revenue to be in the range of $4.3 billion to $4.4 billion, representing an 18.8% year-over-year increase at the midpoint. We expect operating profit to be in the range of $780 million to $820 million, representing approximately a 26% year-over-year increase at the midpoint.
Q4 in particular and Q1 is really all demand-based because, first of all, we took no pricing action in Q4.
As a result, we expect gross margins of hyperscaler revenues to range between 75% to 85%, a level accretive to product revenue gross margins and overall company gross margins.
Everpure rates SELL, Medium conviction. The business trajectory has improved fast, but the stock has improved faster, and at $127.43 investors are paying for a clean FY27-FY28 ramp before free cash flow and margin durability are fully proven. This is not a balance-sheet short or a broken execution story. It is a valuation discipline call against a stock near all-time highs, trading at 142.84x earnings with negative free cash flow. A change to a more positive view would require proof that the FY27 operating profit ramp converts into sustained cash generation and that hyperscaler demand lands with less timing risk than management currently describes.
≣ Full research note tap to expand
Executive Summary
SELL, Medium conviction. Rated SELL, Medium conviction. Everpure's operating story has clearly improved, with FY27 revenue guided to $4.3B-$4.4B, Q4 revenue above $1B for the first time, and eight straight EPS beats, but the stock now trades 2.9% below its 52-week and 5-year high after a 65.22% three-month run. That setup leaves little room for component inflation, hyperscaler lumpiness, or any slippage against a valuation that stands far above peers and far above the quant engine's $69.95 price target.
Investment Thesis
The core issue is not whether Everpure is improving. It is. The issue is whether that improvement is still underappreciated at $127.43. The answer looks no. Management just laid out a much stronger FY27 than the market had expected, with $4.3B-$4.4B of revenue and $780M-$820M of operating profit, after Q4 delivered $1.06B of revenue, $226M of operating profit, and 14.0% EBITDA margin, up 690 bps sequentially. Large-deal momentum was also real, with RPO up 40% and deals over $5M up 80%. This is not a broken story.
But the stock is no longer priced for an improving story. It is priced for a sustained, low-friction scaling story. That distinction matters. FY2026 still showed only $3.7B of revenue growth of 3.4%, EPS of $0.49, down 40.0%, operating margin of just 3.6%, net margin of -21.9%, and FCF of -$0.2B. Against that base, investors are paying 142.84x P/E, 8.48x P/S, and 23.46x book. Even if FY27 unfolds close to plan, the market is already discounting a lot of that upside after the stock's 65.22% three-month run and position 2.9% below the all-time high.
The bear case depends on three things. First, margin normalization is not linear. Management explicitly called out rapid NAND and component inflation, with pricing only partially catching up after an approximately 20% product price increase on Feb. 9. Second, hyperscaler revenue remains back-half weighted and lumpy, tied to customer buildout schedules and testing. Third, the 1touch deal is 1.5% dilutive to FY27 operating profit before turning accretive within 24 months, so reported progress may be less clean than the headline AI narrative suggests.
Conviction stays at Medium, not High, because execution has been undeniably strong. Everpure has beaten EPS in 8 straight quarters, including a +20.7% beat in the most recent report, and the balance sheet is healthy enough to absorb volatility. If the company proves it can convert AI demand into durable free cash flow and maintain operating discipline through the FY27 ramp, the sell case weakens. At this price, though, the market is giving full credit before those proof points are in hand.
Key Metrics
| Metric | Value | Context | ||
|---|---|---|---|---|
| Current price | $127.43 | Reference price for the call | ||
| Quant price target | $69.95 | -45.1% vs current, Low confidence, earnings_growth_blend | ||
| FY2026 revenue | $3.7B | +3.4% YoY | ||
| FY2026 EPS | $0.49 | -40.0% YoY | ||
| FY2026 operating margin | 3.6% | Up from 2.7% in prior FY | ||
| FY2026 net margin | -21.9% | Still deeply negative despite revenue growth | ||
| Valuation | 142.84x P/E | 8.48x P/S | 23.46x P/B | Vs peers at 23.8x P/E and 4.7x P/S |
| FY27 guidance | $4.3B-$4.4B revenue | $780M-$820M operating profit | About 18.8% revenue growth and 26% operating profit growth at midpoint | |
| Balance sheet | 0.15 Debt/Equity | 0.59 Debt/EBITDA | 1.44 current ratio | Leverage is manageable |
| Free cash flow | -$0.2B | Weak cash conversion despite growth narrative | ||
| Price action | +22.56% 1W | +26.89% 1M | +65.22% 3M | Shares are 65.8% above the 200-day average |
| 52-week position | $56.78-$131.29 | Current price is 2.9% below the high |
Financial Strength
The balance sheet is sound enough, and that matters because it removes solvency from the debate. Leverage is low at 0.59 Debt/EBITDA and 0.15 Debt/Equity, with only $0.2B of total debt and a 1.44 current ratio. The problem is economic quality, not financial stress. Everpure is still running with negative free cash flow of $0.2B and a -21.9% net margin, so equity holders are relying on future margin conversion rather than present cash earning power. Management's FY27 operating profit guide suggests that conversion could happen quickly, but until that shows up in cash generation, the stock remains expensive relative to the quality of current earnings.
Competitive Position
Everpure's moat is strengthening, but it is not yet wide enough to justify this valuation on faith alone. The best evidence is operational, not narrative: RPO up 40%, deals over $5M up 80%, first EXA customer landed, and hyperscaler gross margins expected at 75%-85%, which indicates meaningful value in the product mix. Enterprise demand also appears healthy, with management explicitly saying Q4 and Q1 were demand-based rather than pricing-led. The challenge is durability. In AI infrastructure, hardware advantage can narrow quickly if larger vendors close feature gaps or if hyperscalers push more purchasing power into their own supply chains, which management is already standardizing around NAND procurement.
Management & Guidance
Management has earned more credibility than the stock's skeptics may admit. Everpure has posted 8 consecutive EPS beats, including 0.70 vs 0.58 in the latest quarter, and the Q4 call paired strong results with specific guidance. The CFO said, "For fiscal year '27, we anticipate revenue to be in the range of $4.3 billion to $4.4 billion, representing an 18.8% year-over-year increase at the midpoint. We expect operating profit to be in the range of $780 million to $820 million, representing approximately a 26% year-over-year increase at the midpoint." That said, management also acknowledged near-term pressure points, including gross margin compression in Q1 from rapid input-cost inflation, component shortages, and back-half weighted hyperscaler revenue. The guidance looks credible, but not risk-free.
Bull Case
- Guidance strengthened materially: management guided FY27 revenue to $4.3B-$4.4B and FY27 operating profit to $780M-$820M, implying about 26% operating profit growth at the midpoint.
- Demand indicators were strong in Q4, with RPO up 40%, deals over $5M up 80% y/y, and management stating Q4 and Q1 demand was demand-led rather than pricing-led.
- Execution has been consistent: Everpure has delivered 8 straight EPS beats, including +20.7%, +18.2%, and +19.0% beats in the last eight reports.
- The balance sheet is not the problem, with Debt/EBITDA 0.59, Debt/Equity 0.15, and a 1.44 current ratio, giving the company room to fund growth despite near-term cash flow pressure.
Bear Case
- Current valuation already discounts a lot of the FY27 ramp: 142.84x P/E, 23.46x P/B, and 8.48x P/S are difficult to defend against FY2026 EPS of $0.49, down 40.0% y/y.
- Cash generation remains weak relative to the market cap, with FCF of -$0.2B and a net margin of -21.9%, even after revenue grew to $3.7B.
- The recent move has compressed upside and increased setup risk: shares are up 22.56% in 1 week, 26.89% in 1 month, 65.22% in 3 months, and sit 65.8% above the 200-day average.
- Management itself flagged near-term friction, including component shortages, pricing volatility, Q1 product gross margin at the low end of 65%-70% ex-hyperscaler, and a 1.5% FY27 operating profit dilution from 1touch.
Valuation & Price Target
Engine price target $69.95 (-45.1% vs current), Low confidence.
- P/E Multiple: $14.65 (9% weight)
- P/S Multiple: $60.14 (20% weight)
- Quality-adjusted: $117.44 (20% weight)
- DCF: $15.9 (5% weight)
The rating aligns with the quant baseline SELL, but with higher respect for the improving operating trajectory than the low-confidence target alone would imply. The quant engine's $69.95 target is based on a wide blend, including P/E Multiple $14.65, P/S Multiple $60.14, Quality-adjusted $117.44, and DCF $15.9, and the peer framework is noisy because the 9-peer average P/E of 23.8 comes with very wide 12.4x dispersion. Even so, the market is paying 142.84x earnings and 8.48x sales for a company that just posted -$0.2B of free cash flow and -21.9% net margin. Sell-side consensus remains Strong Buy, 14 buy / 1 hold / 1 sell, but that is low-signal context here and does not offset the mismatch between price and still-unproven earnings durability.
Risk Assessment
Risk score 49/100 (Moderate). The biggest risk to a SELL is that Everpure converts its AI and hyperscaler pipeline into sustained operating leverage faster than expected, especially if FY27 operating profit reaches $820M and the emerging $21B intelligence market proves monetizable sooner than the market currently assumes.
The Bottom Line
Everpure rates SELL, Medium conviction. The business trajectory has improved fast, but the stock has improved faster, and at $127.43 investors are paying for a clean FY27-FY28 ramp before free cash flow and margin durability are fully proven. This is not a balance-sheet short or a broken execution story. It is a valuation discipline call against a stock near all-time highs, trading at 142.84x earnings with negative free cash flow. A change to a more positive view would require proof that the FY27 operating profit ramp converts into sustained cash generation and that hyperscaler demand lands with less timing risk than management currently describes.
Go deeper in the app
Live charts, options analytics, the full earnings-call breakdown, price alerts, and every other stock — updated in real time.
Get Tickr